Page 1972 - Williams Hematology ( PDFDrive )

1946 Part XII: Hemostasis and Thrombosis Chapter 113: Molecular Biology and Biochemistry of the Coagulation Factors 1947

306. Hoppe B: Fibrinogen and factor XIII at the intersection of coagulation, fibrinolysis and 338. Massberg S, Grahl L, von Bruehl ML, et al: Reciprocal coupling of coagulation and
inflammation. Thromb Haemost 112:649–658, 2014. innate immunity via neutrophil serine proteases. Nat Med 16:887–896, 2010.
307. Kasahara K, Souri M, Kaneda M, et al: Impaired clot retraction in factor XIII A subun- 339. Sandset PM, Warn-Cramer BJ, Rao LV, et al: Depletion of extrinsic pathway inhibitor
it-deficient mice. Blood 115:1277–1279, 2010. (EPI) sensitizes rabbits to disseminated intravascular coagulation induced with tissue
308. Richardson VR, Cordell P, Standeven KF, Carter AM: Substrates of factor XIII-a: Roles factor: Evidence supporting a physiologic role for EPI as a natural anticoagulant. Proc
in thrombosis and wound healing. Clin Sci (Lond) 124:123–137, 2013. Natl Acad Sci U S A 88:708–712, 1991.
309. Kikuchi H, Kuribayashi F, Imajoh-Ohmi S: Down-regulation of Fas-mediated apoptosis 340. Huang ZF, Higuchi D, Lasky N, Broze GJ Jr: Tissue factor pathway inhibitor gene dis-
by plasma transglutaminase factor XIII that catalyzes fetal-specific cross-link of the Fas ruption produces intrauterine lethality in mice. Blood 90:944–951, 1997.
molecule. Biochem Biophys Res Commun 443:13–17, 2014. 341. Ameziane N, Seguin C, Borgel D, et al: The -33T—>C polymorphism in intron 7 of the
310. Mokuda S, Murata Y, Sawada N, et al: Tocilizumab induced acquired factor XIII defi- TFPI gene influences the risk of venous thromboembolism, independently of the factor
ciency in patients with rheumatoid arthritis. PLoS One 8:e69944, 2013. V Leiden and prothrombin mutations. Thromb Haemost 88:195–199, 2002.
311. Soendergaard C, Kvist PH, Seidelin JB, Nielsen OH: Tissue-regenerating functions of 342. Opstad TB, Eilertsen AL, Hoibraaten E, et al: Tissue factor pathway inhibitor polymor-
coagulation factor XIII. J Thromb Haemost 11:806–816, 2013. phisms in women with and without a history of venous thrombosis and the effects of
312. Weisberg LJ, Shiu DT, Greenberg CS, et al: Localization of the gene for coagulation postmenopausal hormone therapy. Blood Coagul Fibrinolysis 21:516–521, 2010.
factor XIII a-chain to chromosome 6 and identification of sites of synthesis. J Clin Invest 343. Han X, Fiehler R, Broze GJ Jr: Isolation of a protein Z-dependent plasma protease
79:649–652, 1987. inhibitor. Proc Natl Acad Sci U S A 95:9250–9255, 1998.
313. Bottenus RE, Ichinose A, Davie EW: Nucleotide sequence of the gene for the b subunit 344. Tabatabai A, Fiehler R, Broze GJ Jr: Protein Z circulates in plasma in a complex with
of human factor XIII. Biochemistry 29:11195–11209, 1990. protein Z-dependent protease inhibitor. Thromb Haemost 85:655–660, 2001.
314. Muszbek L, Bagoly Z, Cairo A, Peyvandi F: Novel aspects of factor XIII deficiency. Curr 345. Han X, Huang ZF, Fiehler R, Broze GJ Jr: The protein Z-dependent protease inhibitor is
Opin Hematol 18:366–372, 2011. a serpin. Biochemistry 38:11073–11078, 1999.
315. Ichinose A: Factor XIII is a key molecule at the intersection of coagulation and 346. Sejima H, Hayashi T, Deyashiki Y, et al: Primary structure of vitamin K-dependent
fibrinolysis as well as inflammation and infection control. Int J Hematol 95:362–370, human protein Z. Biochem Biophys Res Commun 171:661–668, 1990.
2012. 347. Huang X, Yan Y, Tu Y, et al: Structural basis for catalytic activation of protein Z-depen-
316. Shemirani AH, Antalfi B, Pongracz E, et al: Factor XIII-A subunit Val34Leu polymor- dent protease inhibitor (ZPI) by protein Z. Blood 120:1726–1733, 2012.
phism in fatal atherothrombotic ischemic stroke. Blood Coagul Fibrinolysis 25:364–368, 348. Zhang J, Tu Y, Lu L, et al: Protein Z-dependent protease inhibitor deficiency produces a
2014. more severe murine phenotype than protein Z deficiency. Blood 111:4973–4978, 2008.
317. Foley JH, Kim PY, Mutch NJ, Gils A: Insights into thrombin activatable fibrinolysis 349. Al-Shanqeeti A, van Hylckama Vlieg A, Berntorp E, et al: Protein Z and protein Z-de-
inhibitor function and regulation. J Thromb Haemost 11 Suppl 1:306–315, 2013. pendent protease inhibitor. Determinants of levels and risk of venous thrombosis.
318. van Tilburg NH, Rosendaal FR, Bertina RM: Thrombin activatable fibrinolysis inhibi- Thromb Haemost 93:411–413, 2005.
tor and the risk for deep vein thrombosis. Blood 95:2855–2859, 2000. 350. Almawi WY, Al-Shaikh FS, Melemedjian OK, Almawi AW: Protein Z, an anticoagu-
319. Seegers WH, Johnson JF, Fell C: An antithrombin reaction to prothrombin activation. lant protein with expanding role in reproductive biology. Reproduction 146:R73–R80,
Am J Physiol 176:97–103, 1954. 2013.
320. Huntington JA: Serpin structure, function and dysfunction. J Thromb Haemost 9 Suppl 351. Van de Water N, Tan T, Ashton F, et al: Mutations within the protein Z-dependent pro-
1:26–34, 2011. tease inhibitor gene are associated with venous thromboembolic disease: A new form
321. Olson ST, Swanson R, Raub-Segall E, et al: Accelerating ability of synthetic oligosac- of thrombophilia. Br J Haematol 127:190–194, 2004.
charides on antithrombin inhibition of proteinases of the clotting and fibrinolytic sys- 352. Young LK, Birch NP, Browett PJ, et al: Two missense mutations identified in venous
tems. Comparison with heparin and low-molecular-weight heparin. Thromb Haemost thrombosis patients impair the inhibitory function of the protein Z dependent protease
92:929–939, 2004. inhibitor. Thromb Haemost 107:854–863, 2012.
322. Olson ST, Bjork I: Predominant contribution of surface approximation to the mecha- 353. McQuillan AM, Eikelboom JW, Hankey GJ, et al: Protein Z in ischemic stroke and its
nism of heparin acceleration of the antithrombin-thrombin reaction. Elucidation from etiologic subtypes. Stroke 34:2415–2419, 2003.
salt concentration effects. J Biol Chem 266:6353–6364, 1991. 354. Dossenbach-Glaninger A, van Trotsenburg M, Helmer H, et al: Association of the pro-
323. Li W, Johnson DJ, Esmon CT, Huntington JA: Structure of the antith- tein Z intron F G79A gene polymorphism with recurrent pregnancy loss. Fertil Steril
rombin-thrombin-heparin ternary complex reveals the antithrombotic mechanism of 90:1155–1160, 2008.
heparin. Nat Struct Mol Biol 11:857–862, 2004. 355. Grandone E, Colaizzo D, Cappucci F, et al: Protein Z levels and unexplained fetal losses.
324. Pizzo SV: Serpin receptor 1: A hepatic receptor that mediates the clearance of antith- Fertil Steril 82:982–983, 2004.
rombin III-proteinase complexes. Am J Med 87(3B):10S–14S, 1989. 356. Macfarlane RG: An enzyme cascade in the blood clotting mechanism, and its function
325. Kounnas MZ, Church FC, Argraves WS, Strickland DK: Cellular internalization and as a biochemical amplifier. Nature 202:498–499, 1964.
degradation of antithrombin III-thrombin, heparin cofactor II-thrombin, and alpha 357. Davie EW, Ratnoff OD: Waterfall sequence for intrinsic blood clotting. Science
1-antitrypsin-trypsin complexes is mediated by the low density lipoprotein receptor-re- 145:1310–1312, 1964.
lated protein. J Biol Chem 271:6523–6529, 1996. 358. Pitlick FA, Nemerson Y: Purification and characterization of tissue factor apoprotein.
326. Tait RC, Walker ID, Perry DJ, et al: Prevalence of antithrombin deficiency in the healthy Methods Enzymol 45:37–48, 1976.
population. Br J Haematol 87:106–112, 1994. 359. Mackman N, Morrissey JH, Fowler B, Edgington TS: Complete sequence of the human
327. Harper PL, Luddington RJ, Daly M, et al: The incidence of dysfunctional antithrombin tissue factor gene, a highly regulated cellular receptor that initiates the coagulation pro-
variants: Four cases in 210 patients with thromboembolic disease. Br J Haematol tease cascade. Biochemistry 28:1755–1762, 1989.
77:360–364, 1991. 360. Osterud B, Rapaport SI: Activation of factor IX by the reaction product of tissue factor
328. Lane DA, Bayston T, Olds RJ, et al: Antithrombin mutation database: 2nd (1997) and factor VII: Additional pathway for initiating blood coagulation. Proc Natl Acad Sci
update. For the Plasma Coagulation Inhibitors Subcommittee of the Scientific and U S A 74:5260–5264, 1977.
Standardization Committee of the International Society on Thrombosis and Haemo- 361. Repke D, Gemmell CH, Guha A, et al: Hemophilia as a defect of the tissue factor path-
stasis. Thromb Haemost 77:197–211, 1997. way of blood coagulation: Effect of factors VIII and IX on factor X activation in a con-
329. Broze GJ Jr, Miletich JP: Isolation of the tissue factor inhibitor produced by HepG2 tinuous-flow reactor. Proc Natl Acad Sci U S A 87:7623–7627, 1990.
hepatoma cells. Proc Natl Acad Sci U S A 84:1886–1890, 1987. 362. van ‘t Veer C, Hackeng TM, Delahaye C, et al: Activated factor X and thrombin forma-
330. Novotny WF, Girard TJ, Miletich JP, Broze GJ Jr: Purification and characterization tion triggered by tissue factor on endothelial cell matrix in a flow model: Effect of the
of the lipoprotein-associated coagulation inhibitor from human plasma. J Biol Chem tissue factor pathway inhibitor. Blood 84:1132–1142, 1994.
264:18832–18837, 1989. 363. van ‘t Veer C, Mann KG: Regulation of tissue factor initiated thrombin generation by
331. Girard TJ, Warren LA, Novotny WF, et al: Functional significance of the Kunitz- the stoichiometric inhibitors tissue factor pathway inhibitor, antithrombin-III, and
type inhibitory domains of lipoprotein-associated coagulation inhibitor. Nature heparin cofactor-II. J Biol Chem 272:4367–4377, 1997.
338:518–520, 1989. 364. Hilden I, Lauritzen B, Sorensen BB, et al: Hemostatic effect of a monoclonal antibody
332. Wood JP, Ellery PE, Maroney SA, Mast AE: Biology of tissue factor pathway inhibitor. mAb 2021 blocking the interaction between FXa and TFPI in a rabbit hemophilia
Blood 123:2934–2943, 2014. model. Blood 119:5871–5878, 2012.
333. Hackeng TM, Sere KM, Tans G, Rosing J: Protein S stimulates inhibition of the tissue 365. Carmeliet P, Mackman N, Moons L, et al: Role of tissue factor in embryonic blood
factor pathway by tissue factor pathway inhibitor. Proc Natl Acad Sci U S A vessel development. Nature 383:73–75, 1996.
103:3106–3111, 2006. 366. Gailani D, Broze GJ Jr: Factor XI activation in a revised model of blood coagulation.
334. Ndonwi M, Tuley EA, Broze GJ Jr: The Kunitz-3 domain of TFPI-alpha is required for Science 253:909–912, 1991.
protein S-dependent enhancement of factor Xa inhibition. Blood 116:1344–1351, 2010. 367. Nemerson Y: The tissue factor pathway of blood coagulation. Semin Hematol 29:170–
335. Wood JP, Bunce MW, Maroney SA, et al: Tissue factor pathway inhibitor-alpha inhibits 176, 1992.
prothrombinase during the initiation of blood coagulation. Proc Natl Acad Sci U S A 368. Esmon CT: The protein C pathway. Chest 124(Suppl 3):26S–32S, 2003.
110:17838–17843, 2013. 369. Holmer E, Kurachi K, Soderstrom G: The molecular-weight dependence of the rate-en-
336. Dahm A, Van Hylckama Vlieg A, Bendz B, et al: Low levels of tissue factor pathway hancing effect of heparin on the inhibition of thrombin, factor Xa, factor IXa, factor
inhibitor (TFPI) increase the risk of venous thrombosis. Blood 101:4387–4392, 2003. XIa, factor XIIa and kallikrein by antithrombin. Biochem J 193:395–400, 1981.
337. Castoldi E, Simioni P, Tormene D, et al: Hereditary and acquired protein S deficiencies 370. Brummel-Ziedins KE, Everse SJ, Mann KG, Orfeo T: Modeling thrombin generation:
are associated with low TFPI levels in plasma. J Thromb Haemost 8:294–300, 2010. Plasma composition based approach. J Thromb Thrombolysis 37:32–44, 2014.

Kaushansky_chapter 113_p1915-1948.indd 1947 9/21/15 2:41 PM